Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar 30;14(3):503-506.
doi: 10.21037/tau-2024-743. Epub 2025 Mar 26.

Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer

Nuowei Wang  1 , Karl H Tully  1
Affiliations
Editorial

Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer

Nuowei Wang et al. Transl Androl Urol. .
No abstract available

Keywords: Bladder cancer; adverse events; antibody-drug conjugate (ADC); metastatic disease; quality of life.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-743/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Rosenberg JE, Mamtani R, Sonpavde GP, et al. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol 2024;85:574-85. 10.1016/j.eururo.2024.01.007 - DOI - PMC - PubMed
    1. Churruca K, Pomare C, Ellis LA, et al. Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues. Health Expect 2021;24:1015-24. 10.1111/hex.13254 - DOI - PMC - PubMed
    1. Reike MJ, Bahlburg H, Brehmer M, et al. Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer. Cancer Epidemiol 2024;90:102574. 10.1016/j.canep.2024.102574 - DOI - PubMed
    1. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35. 10.1056/NEJMoa2035807 - DOI - PMC - PubMed
    1. Yang H, Yu X, An Z. Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System. Front Oncol 2021;11:801199. 10.3389/fonc.2021.801199 - DOI - PMC - PubMed